Navigation Links
Celator(R) Pharmaceuticals Reports CPX-351 Shows Anti-Cancer Activity in Leukemia Patients
Date:12/10/2007

Results from ongoing Phase I study of advanced leukemia and myelodysplastic syndrome patients presented at American Society for Hematology meeting.

PRINCETON, N.J., Dec. 10 /PRNewswire/ -- Celator Pharmaceuticals today announced results from an ongoing Phase I study of CPX-351, a liposomal formulation that incorporates a synergistic ratio of cytarabine and daunorubicin for the treatment of advanced leukemias and myelodysplastic syndromes. While dose escalation in the study is ongoing, thus far three patients treated with CPX-351 have achieved complete remissions (CR), one patient has achieved a CRp (complete remission where platelets did not recover to greater than 100,000 platelets per microliter), and two additional patients achieved partial remissions (PR).

The study included patients with relapsed/refractory acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL) and high-risk myelodysplastic syndrome (MDS). All but three of the 27 patients had AML. The majority of patients were older than 60 years of age, including four patients older than 75. All patients had relapsed or refractory disease, with 15/27 having received two or more prior induction therapies. After their last therapy, 19/27 had no response and 8/27 achieved a CR. CPX-351 has been safely administered up to and including 101 units/m2 (=101 mg/m2 of cytarabine and 44mg/m2 of daunorubicin). Non-hematologic adverse events included stomatitis (10/27 patients), skin rash (10/27), diarrhea (9/27), nausea (7/27), vomiting (5/27) and alopecia (2/27). The study has shown that CPX-351 is capable of inducing marrow aplasia with few severe non-hematologic adverse events.

"CPX-351 is a provocative new treatment approach for patients with AML," said Eric Feldman, MD, from Weill Medical College of Cornell University and New York Presbyterian Hospital and an investigator in the Phase I study. "The data from the Phase I study in highly refractory AML patients are encouraging, includi
'/>"/>

SOURCE Celator Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... March 27, 2015 /CNW/ - Covalon Technologies Ltd. (the ... company, today announced the issuance of an aggregate of ... Company and an aggregate of 120,500 stock options to ... will vest over three years and will be exercisable ... price of $1.40 per stock option. About ...
(Date:3/27/2015)... /PRNewswire/ - Medicure Inc. (the "Company") (TSXV:MPH, OTCQB:MCUJF) announces ... grant of an aggregate of 236,070 options to certain ... the Company pursuant to the Company,s Stock Option Plan. ... the tenth anniversary of the date of grant, 5,000 ... the date of grant and 50,000 are set to ...
(Date:3/27/2015)... , March 27, 2015  Holographic Optical Technologies ... the field of holographic medical imaging, is entering the ... Kickstarter campaign. Launching on April 20 th , 2015, ... Voxbox Pro. The 8-inch and 22-inch displays will allow ... for the first time. In addition to the two ...
Breaking Medicine Technology:Covalon Announces Issuance of Stock Options 2Holographic Optical Technologies brings cutting-edge holograms to consumer market through upcoming Kickstarter campaign 2Holographic Optical Technologies brings cutting-edge holograms to consumer market through upcoming Kickstarter campaign 3
... 23, 2011 Reportlinker.com announces that a new ... Global Medical Imaging Equipment ... This report analyzes the worldwide ... Million by the following Product segments: OEM (Original ...
... announces that a new market research report is available ... Kits and Trays Industry http://www.reportlinker.com/p090645/Global-Prepackaged-Medical-Kits-and-Trays-Industry.html ... markets for Prepackaged Medical Kits and Trays in US$ ... Ophthalmic Custom Trays, Custom or Basin Kits, Custom Ob/Gyn, ...
Cached Medicine Technology:Reportlinker Adds Global Medical Imaging Equipment Services Industry 2Reportlinker Adds Global Prepackaged Medical Kits and Trays Industry 2
(Date:3/28/2015)... March 28, 2015 Thousands of ... manufactured by C.R. Bard, Inc. continue to move ... District Court, Southern District of West Virginia, where ... on the Plaintiffs’ Steering Committee. According to ... granted certain defendants named in those lawsuits leave ...
(Date:3/28/2015)... India Network visitor health insurance announced ... visitors who purchase the plan before arrival in the ... purchase the insurance program as soon as travel plans ... pre-existing medical conditions. Parents and grandparents traveling from India ... serious consequences to their health. Many visitors may not ...
(Date:3/28/2015)... 28, 2015 Pitching speed, player’s height, and ... shoulder and elbow injuries, according to new research released today ... ) Specialty Day. , “Our findings indicate that a 10 ... in likelihood of a history of injury, a 10 mile ... increase likelihood of a history of injury, and playing for ...
(Date:3/28/2015)... March 28, 2015 Delaying rotator cuff ... necessary, according to research presented today at the American ... Day. , “Our study compared results for 170 patients ... an additional glenohumeral joint capsule release procedure to relieve ... MD, PhD, lead author from St. George Hospital in ...
(Date:3/28/2015)... Andrew Hawley of Vintage Rock Posters Inc., ... posters. The Who and the Doors played together at the ... According to Hawley, “The Who toured the United States heavily ... campuses. Perhaps the most famous Who poster was a poster ... Doors on August 2, 1968 at the Singer Bowl in ...
Breaking Medicine News(10 mins):Health News:Federal C.R. Bard Vaginal Mesh Lawsuits Move Forward, As Court Grants Defense Motion to Amend Responses to Master Complaint 2Health News:Federal C.R. Bard Vaginal Mesh Lawsuits Move Forward, As Court Grants Defense Motion to Amend Responses to Master Complaint 3Health News:Federal C.R. Bard Vaginal Mesh Lawsuits Move Forward, As Court Grants Defense Motion to Amend Responses to Master Complaint 4Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 2Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 3Health News:Researchers Highlight Shoulder and Elbow Injury Possibility in Youth Players 2Health News:No Need to Delay Rotator Cuff Surgery, Study Shows 2Health News:Avid Collector from Vintage Rock Posters, Inc. Announces His Search For Original 1960's Who Psychedelic Concert Posters. 2
... , , , ... Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that it was ... to be submitted for a Marketing Authorization Application ("MAA") through the ... coordinated review for approval of pharmaceutical products that is conducted by ...
... health care reform measures, Rush University Medical Center has launched ... from hospital to home. The goal of ... two years ago, succeeds in reducing readmissions within 30 days ... model for hospitals across the country that are seeking ways ...
... DETROIT, July 28 Caraco Pharmaceutical Laboratories, Ltd. ... Doshi has been appointed as interim Chief Executive Officer and ... Daniel H. Movens as Chief Executive Officer and as a ... Movens, tenure, Caraco experienced substantial product expansion and revenue growth. ...
... is pondering, , TUESDAY, July 28 (HealthDay News) -- A ... raise the age at which American women should start Pap ... age at which a woman should first have a Pap ... States, however, women are told to get regular Pap smears ...
... do not appear to increase cancer risk. A large meta-analysis, published ... that snuff as used in Scandinavia has no discernible effect on ... the USA may have increased the risk, but any effect that ... and Jan Hamling, from P.N. Lee Statistics and Computing Ltd, carried ...
... , NEW YORK, July 28 Finding time to ... especially during stressful times. Here,s more on a how you can ... Listen to this report from Kellogg,s at: , ... can access video, audio, text, graphics and photos for free and unrestricted ...
Cached Medicine News:Health News:Cell Therapeutics Initiates Process to Obtain Marketing Approval for Pixantrone in Europe 2Health News:Cell Therapeutics Initiates Process to Obtain Marketing Approval for Pixantrone in Europe 3Health News:Cell Therapeutics Initiates Process to Obtain Marketing Approval for Pixantrone in Europe 4Health News:Rush University Medical Center studies program to help older adults transition from hospital to home 2Health News:Caraco Pharmaceutical Laboratories, Ltd. Announces Change to Executive Team as Jitendra N. Doshi Assumes Position of CEO 2Health News:Teens May Not Benefit from Pap Tests 2Health News:Teens May Not Benefit from Pap Tests 3
... surgery and other types of refractive surgery. ... stromal bed. Flattened tip provides easy insertion ... flap edge. Multiple ports provide multi-directional irrigation. ... 7mm from end. Two .15mm ports 2mm, ...
... designed for LASIK surgery and other ... irrigate the corneal interface and/or stromal ... under the flap and helps elevate ... multi-directional irrigation. 21G x 7/8in (.80 ...
Cannula tip is specially rounded, extra smooth for safe insertion through wound and manipulation in the anterior chamber. 23G x 7/8 in (.60 x 22mm). .3mm end port. Olive shape tip is 2mm long x 1mm w...
For injecting anesthetics into the muscle cone. 25G x 1 1/2 in (.50 x 38mm)...
Medicine Products: